Prostate Cancer – Landscape & Forecast – Disease Landscape & Forecast
Hormonal agents are the mainstay treatment for prostate cancer and are routinely used in all lines of therapy. Next-generation hormonal treatment has expanded beyond metastatic castrate-resistant prostate cancer (mCRPC), impacting current treatment algorithms for nonmetastatic CRPC and metastatic hormone-sensitive prostate cancer (HSPC). Some patients with mCRPC are receiving triple combinations of current therapies. The dynamic late-phase pipeline mostly focuses on mCRPC and comprises a plethora of targeted agents (e.g., Janssen / GlaxoSmithKline’s Zejula, Pfizer’s Talzenna, Roche’s ipatasertib, AstraZeneca’s capivasertib) and novel prostate-specific membrane antigen (PSMA)-targeted radioligands (e.g., Novartis’s 177Lu-PSMA-617, Telix’s 77Lu-DOTA-rosopatamab, POINT Biopharma’s 177Lu-PNT2002). These agents will likely contribute to robust market growth over the 2021-2031 forecast period.
QUESTIONS ANSWERED
- What are the sizes of the clinically and commercially relevant drug-treatable prostate cancer populations, and how will drug-treatment rates change over time?
- What are the key drivers and constraints in the prostate cancer therapy market, and how will the major markets evolve over the 10-year forecast period?
- What is the current state of treatment for prostate cancer? What are interviewed experts’ insights on these treatment options?
- What is the clinical and commercial potential of late-phase pipeline products, and what will their positioning and uptake in the market be?
PRODUCT DESCRIPTION
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
SOLUTION ENHANCEMENT
Disease Landscape & Forecast will feature continual updates in 2022 to provide timely insights and analyses as meaningful indication-specific news and events unfold.
Additionally, Disease Landscape & Forecast introduces a new Drug Pipeline chapter with real-time, global pipeline intelligence content directly from Cortellis. This chapter is updated daily and features interactive figures that can be easily downloaded for detailed analysis or presentations.
Table of contents
- Prostate Cancer - Landscape & Forecast - Disease Landscape & Forecast
- Key findings
- Prostate Cancer Key Findings
- Key updates
- January 2023
- Q4 2022
- December 2022
- October 2022
- Q3 2022
- September 2022
- August 2022
- Q2 2022
- May 2022
- April 2022
- Market outlook
- Key findings
- Major-market share of prostate cancer drug classes: 2021
- Major-market sales of prostate cancer drug classes: 2031
- Drug-treatable population share and major-market sales share: 2021
- Drug-treatable population share and major-market sales share: 2031
- Population positioning of therapies in prostate cancer
- Prostate cancer SWOT analysis
- Market drivers and constraints
- What factors are driving the market for prostate cancer?
- What factors are constraining the market for prostate cancer?
- Major-market sales of key agents for prostate cancer: 2021-2031
- Major-market sales for prostate cancer by region: 2021, 2026, and 2031
- Major-market sales for prostate cancer by drug class: 2021-2031
- Segment-specific trends
- Major-market share of key agents for metastatic hormone-sensitive prostate cancer: 2031
- Patient-share dynamics of key agents for newly diagnosed high-risk and N1M0 hormone-sensitive prostate cancer in the United States: 2021-2031
- Patient-share dynamics of key agents for biochemically recurrent hormone-sensitive prostate cancer in the United States: 2021-2031
- Patient-share dynamics of key agents for metastatic hormone-sensitive prostate cancer in the United States: 2021-2031
- Patient-share dynamics of key hormonal agents for nonmetastatic castrate-resistant prostate cancer in the United States: 2021-2031
- Patient-share dynamics of key therapies in first-line metastatic castrate-resistant prostate cancer in the United States: 2021-2031
- Patient-share dynamics of key therapies in first-line metastatic castrate-resistant prostate cancer in France: 2021-2031
- Share of major-market sales in first-line metastatic castrate-resistant prostate cancer by agent: 2031
- Patient-share dynamics of key therapies in second-line metastatic castrate-resistant prostate cancer in the United States: 2021-2031
- Patient-share dynamics of key therapies in second-line metastatic castrate-resistant prostate cancer in France: 2021-2031
- Patient-share dynamics of key therapies in third- and fourth-line metastatic castrate-resistant prostate cancer in the United States: 2021-2031
- Patient-share dynamics of key therapies in third- and fourth-line metastatic castrate-resistant prostate cancer in France: 2021-2031
- Share of major-market sales in second- and subsequent-line metastatic castrate-resistant prostate cancer by drug class: 2031
- Key findings
- Forecast
- Market forecast assumptions
- Market forecast dashboard
- Etiology and pathophysiology
- Key findings
- Disease overview
- Disease pathophysiology
- Biology and metastatic spread of prostate cancer
- Development of castrate-resistant prostate cancer
- Molecular alterations involved in castrate-resistant prostate cancer
- Prostate-specific antigen
- Key clinical uses of prostate-specific antigen as a biomarker in prostate cancer
- Staging classification and grading systems for prostate cancer
- TNM staging classification system for prostate cancer
- Classification of level of risk of recurrence of prostate cancer
- Key pathways and drug targets
- Androgen receptor-signaling pathway
- Androgen-mediated growth of normal and cancerous prostate cells
- Splice variants of the androgen receptor
- Emerging drug targets in prostate cancer
- PARP inhibition: mechanism of action
- Immune checkpoint inhibitors and modulators
- Anatomic location and architecture of the prostate gland
- Key findings
- Epidemiology
- Key findings
- Key updates
- Epidemiology populations
- Disease definition
- Methods
- Sources used for diagnosed incidence of prostate cancer
- Number of diagnosed incident cases of prostate cancer in the major pharmaceutical markets: 2021-2031
- Disease definition
- Methods
- Sources used for TNM stage and NCCN risk categories of prostate cancer
- Diagnosed incident cases of prostate cancer in the major pharmaceutical markets by TNM stage and NCCN risk category: 2021-2031
- Disease definition
- Methods
- Sources used for recurrent incidence of prostate cancer
- Number of biochemically and metastatic recurrent incident cases of prostate cancer in the major pharmaceutical markets: 2021-2031
- Sources used for drug-treatable prostate cancer population
- Drug-treatable cases of prostate cancer in the major pharmaceutical markets: 2021-2031
- Prostate cancer patient-flow model
- Sources used for prostate cancer drug-treated population
- Drug-treated cases of prostate cancer in the major pharmaceutical markets: 2021-2031
- Key findings
- Current treatment
- Key findings
- Treatment goals
- Key endpoints used in clinical trials for prostate cancer
- Key current therapies
- Overview
- Mechanism of action of key current drug classes used for prostate cancer
- Current treatments used for prostate cancer
- Market events impacting the use of key current therapies for prostate cancer
- Advantages and disadvantages of Zytiga
- Key results from clinical trials investigating Zytiga for the treatment of prostate cancer
- Ongoing clinical development of Zytiga
- Key ongoing clinical trials of Zytiga in the treatment of prostate cancer
- Expert insight: Zytiga
- Advantages and disadvantages of Xtandi
- Key results from clinical trials investigating Xtandi for the treatment of prostate cancer
- Ongoing clinical development of Xtandi
- Key ongoing clinical trials of Xtandi in the treatment of prostate cancer
- Expert insight: Xtandi
- Key results from select clinical trials investigating Erleada for the treatment of prostate cancer
- Ongoing clinical development of Erleada
- Expert insight: Erleada
- Key results from select clinical trials investigating Nubeqa for the treatment of prostate cancer
- Ongoing clinical development of Nubeqa
- Key ongoing clinical trials of Nubeqa in the treatment of prostate cancer
- Expert insight: Nubeqa
- Key results from select clinical trials investigating Yonsa for the treatment of prostate cancer
- Expert insight: Yonsa
- Advantages and disadvantages of LHRH agonists / antagonists
- Expert insight: LHRH agonists / antagonists
- Key results from select clinical trials investigating Orgovyx for the treatment of prostate cancer
- Ongoing clinical development of Orgovyx
- Expert insight: Orgovyx
- Key results from select clinical trials investigating Pluvicto for the treatment of prostate cancer
- Ongoing clinical development of Pluvicto
- Key ongoing clinical trials of Pluvicto in the treatment of prostate cancer
- Expert insight: Pluvicto
- Advantages and disadvantages of Provenge
- Key results from clinical trials investigating Provenge for the treatment of prostate cancer
- Ongoing clinical development of Provenge
- Key ongoing clinical trials investigating Provenge in the treatment of prostate cancer
- Expert insight: Provenge
- Advantages and disadvantages of Xofigo
- Key results from clinical trials investigating Xofigo for the treatment of prostate cancer
- Ongoing clinical development of Xofigo
- Key ongoing clinical trials of Xofigo in the treatment of prostate cancer
- Expert insight: Xofigo
- Advantages and disadvantages of Jevtana
- Key results from clinical trials investigating Jevtana for the treatment of prostate cancer
- Ongoing clinical development of Jevtana
- Expert insight: Jevtana
- Advantages and disadvantages of docetaxel
- Key results from clinical trials investigating docetaxel for the treatment of prostate cancer
- Expert insight: docetaxel
- Key results from select clinical trials investigating Lynparza for the treatment of prostate cancer
- Ongoing clinical development of Lynparza
- Key ongoing clinical trials of Lynparza in the treatment of prostate cancer
- Expert insight: Lynparza
- Key results from clinical trials investigating Rubraca for the treatment of prostate cancer
- Ongoing clinical development of Rubraca
- Key ongoing clinical trials of Rubraca in the treatment of prostate cancer
- Expert insight: Rubraca
- Medical practice
- Newly diagnosed low- and intermediate-risk hormone-sensitive prostate cancer
- Newly diagnosed high-risk and N1M0 hormone-sensitive prostate cancer
- Metastatic hormone-sensitive prostate cancer
- Biochemically recurrent prostate cancer
- Nonmetastatic castrate-resistant prostate cancer
- First-line metastatic castrate-resistant prostate cancer
- Second- and subsequent-line metastatic castrate-resistant prostate cancer
- Patient characteristics influencing drug selection in prostate cancer
- Treatment decision tree for low- and intermediate-risk prostate cancer: major markets
- Treatment decision tree for high-risk and N1M0 prostate cancer: major markets
- Treatment decision tree for nonmetastatic castrate-resistant prostate cancer: United States
- Treatment decision tree for metastatic hormone-sensitive prostate cancer: United States
- Treatment decision tree for metastatic castrate-resistant prostate cancer: major markets
- Key findings
- Unmet need overview
- Current and future attainment of unmet needs in prostate cancer
- Top unmet needs in prostate cancer: current and future attainment
- Expert insight: unmet need in prostate cancer
- Drug pipeline
- Pipeline
- Regulatory Milestones
- Indication Comparison
- Emerging therapies
- Key findings
- Key emerging therapies
- Key therapies in development for prostate cancer
- Estimated market authorization dates of key emerging therapies for the treatment of prostate cancer
- Key results from select clinical trials investigating CAN-2409 for the treatment of prostate cancer
- Analysis of clinical development program for CAN-2409
- Key ongoing clinical trials of CAN-2409 in the treatment of prostate cancer
- Expert insight: CAN-2409
- Expectations for market authorization and sales opportunity of CAN-2409 in prostate cancer
- Key results from clinical trials investigating Keytruda for the treatment of prostate cancer
- Analysis of clinical development program for Keytruda
- Key ongoing clinical trials of Keytruda in the treatment of prostate cancer
- Expert insight: Keytruda
- Expectations for market authorization and sales opportunity of Keytruda in prostate cancer
- Key results from clinical trials investigating Opdivo for the treatment of prostate cancer
- Analysis of clinical development program for Opdivo
- Key ongoing clinical trials of Opdivo in the treatment of prostate cancer
- Expert insight: Opdivo
- Expectations for market authorization and sales opportunity of Opdivo in prostate cancer
- Key results from clinical trials investigating Talzenna for the treatment of prostate cancer
- Analysis of clinical development program for Talzenna
- Key ongoing clinical trials of Talzenna in the treatment of prostate cancer
- Expert insight: Talzenna
- Expectations for market authorization and sales opportunity of Talzenna in prostate cancer
- Key results from clinical trials investigating Zejula for the treatment of prostate cancer
- Analysis of clinical development program for Zejula
- Key ongoing clinical trials of Zejula in the treatment of prostate cancer
- Expert insight: Zejula
- Expectations for launch and sales opportunity of Zejula in prostate cancer
- Key results from select clinical trials investigating ipatasertib for the treatment of prostate cancer
- Analysis of clinical development program for ipatasertib
- Expert insight: ipatasertib
- Expectations for market authorization and sales opportunity of ipatasertib in prostate cancer
- Key results from select clinical trials investigating capivasertib for the treatment of prostate cancer
- Analysis of clinical development program for capivasertib
- Key ongoing clinical trials of capivasertib in the treatment of prostate cancer
- Expert insight: capivasertib
- Expectation for market authorization and sales opportunity of capivasertib in prostate cancer
- Key results from select clinical trials investigating 177Lu-DOTA-rosopatamab for the treatment of prostate cancer
- Analysis of the clinical development program for 177Lu-DOTA-rosopatamab
- Key ongoing clinical trials of 177Lu-DOTA-rosopatamab in the treatment of prostate cancer
- Expert insight: 177Lu-DOTA-rosopatamab
- Expectations for market authorization and sales opportunity of 177Lu-DOTA-rosopatamab in prostate cancer
- Key results from select clinical trials investigating 177Lu-PNT2002 for the treatment of prostate cancer
- Analysis of the clinical development program for 177Lu-PNT2002
- Key ongoing clinical trials of 177Lu-PNT2002 in the treatment of prostate cancer
- Expert insight: 177Lu-PNT2002
- Expectations for market authorization and sales opportunity of 177Lu-PNT2002 in prostate cancer
- Analysis of the clinical development program for 177Lu-PSMA-I&T
- Key ongoing clinical trials of 177Lu-PSMA-I&T in the treatment of prostate cancer
- Expert insight: 177Lu-PSMA-I&T
- Expectations for market authorization and sales opportunity of 177Lu-PSMA-I&T in prostate cancer
- Key results from select clinical trials investigating sabizabulin (VERU-111) for the treatment of prostate cancer
- Analysis of the clinical development program for sabizabulin (VERU-111)
- Key ongoing clinical trials of sabizabulin (VERU-111) in the treatment of prostate cancer
- Expert insight: sabizabulin (VERU-111)
- Expectations for market authorization and sales opportunity of sabizabulin (VERU-111) in prostate cancer
- Key results from select clinical trials investigating Cabometyx for the treatment of prostate cancer
- Analysis of clinical development program for Cabometyx
- Key ongoing clinical trials of Cabometyx in the treatment of prostate cancer
- Expert insight: Cabometyx
- Expectations for market authorization and sales opportunity of Cabometyx in prostate cancer
- Analysis of the clinical development program for Verzenio / Verzenios
- Key ongoing clinical trials of Verzenio / Verzenios in the treatment of prostate cancer
- Expert insight: Verzenio / Verzenios
- Expectations for market authorization and sales opportunity of Verzenio / Verzenios in prostate cancer
- Key results from clinical trials investigating vobramitamab duocarmazine for the treatment of prostate cancer
- Analysis of the clinical development program for vobramitamab duocarmazine
- Key ongoing clinical trials of vobramitamab duocarmazine in the treatment of prostate cancer
- Expectations for market authorization and sales opportunity of vobramitamab duocarmazine in prostate cancer
- Early-phase pipeline analysis
- Select compounds in early-phase development for prostate cancer
- Key findings
- Access and reimbursement overview
- Region-specific reimbursement practices
- Key market access considerations in prostate cancer: United States
- General reimbursement environment: United States
- Key market access considerations in prostate cancer: EU5
- General reimbursement environment: EU5
- Key market access considerations in prostate cancer: Japan
- General reimbursement environment: Japan
- Region-specific reimbursement practices
- Appendix
- Abbreviations
- Brands, Marketers, and Generic Availability of Current Therapies Used for Prostate Cancer by Market
- Prostate cancer bibliography
- Key findings
Saurabh Virdi, B.Tech., Lead Healthcare Research & Data Analyst, Oncology. Mr. Virdi has more than seven years working in the pharmaceutical industry providing analytical support in various therapy areas, including oncology, HIV, vaccines, specialty pharma, and rare diseases. Prior to joining Clarivate, he was an assistant project manager at DelveInsight Business Research LLP, where he was responsible for developing and delivering customized market and asset value forecasts. Before DelveInsight, he worked at WNS GSK Knowledge center and SmartAnalyst, where, as part of multifunctional teams, he helped clients’ decision making throughout the development journey from early-stage to marketed drugs. He obtained his bachelor’s degree in biotechnology from Delhi Technological University in India.
Narendra Parihar, B.D.S., M.P.H., Senior Manager, Epidemiology. Dr Parihar is a team lead at Clarivate Epidemiology. He specializes in modelling and forecasting epidemiology patient populations across multiple indications. His primary areas of interest are cancer epidemiology, rare disease epidemiology, and targeted therapies in cancer. His qualifications include a master’s degree in public health with specialization in health policy, economics, and finance from Tata Institute of Social Sciences Mumbai, and a bachelor’s degree in dental surgery from the Rajasthan University of Health Sciences.